What is Ligand Pharmaceuticals's net debt / EBITDA?

Ligand Pharmaceuticals (LGND) reported net debt / EBITDA of -0.9× in Q1 2026.

What is the long-term trend for Ligand Pharmaceuticals's net debt / EBITDA?

Over 5 years (2020 to 2025), Ligand Pharmaceuticals's net debt / EBITDA has grown at a 39.5% compound annual growth rate (CAGR), from -0.4× to -2.3×.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.

Ligand Pharmaceuticals LGND Net debt / EBITDA

Net debt / EBITDA at other companies

Royalty PharmaRPRX

5.2×+1.4×

RevvityRVTY

4×+1.2×

Roivant SciencesROIV

-0×—

Kiniksa Pharmaceuticals International, plcKNSA

-1.9×—

ALN

Alnylam PharmaceuticalsALNY

-1.8×—

Bristol-Myers SquibbBMY

2.7×-0.1×

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Calculated from Ligand Pharmaceuticals’s reported figures.

net debt/ebitda=-0.9×

Based on the most recent quarter.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's net debt / EBITDA?: Ligand Pharmaceuticals (LGND) reported net debt / EBITDA of -0.9× in Q1 2026.
What is the long-term trend for Ligand Pharmaceuticals's net debt / EBITDA?: Over 5 years (2020 to 2025), Ligand Pharmaceuticals's net debt / EBITDA has grown at a 39.5% compound annual growth rate (CAGR), from -0.4× to -2.3×.
What does net debt / EBITDA mean?: Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.